ArticleJAMA2010
Time for oncologists to opt in for routine opt-out HIV testing?
Article in JAMA, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Guideline
- Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Cancer epidemiology and survival in a high HIV prevalence region of Kenya: a 10-year retrospective cohort study.medRxiv : the preprint server for health sciences · 2026Article
- Quality improvement report: Investigating barriers in HIV testing oncology patients to optimize HIV testing practice.HIV medicine · 2025Article
- HIV Screening among Patients with Newly Diagnosed Solid and Hematologic Malignancies in a Tertiary Hospital in the Philippines.Acta medica Philippina · 2024Article
- Characterizing HIV status documentation among cancer patients at regional cancer centers in Malawi, Zimbabwe, and South Africa.Infectious agents and cancer · 2023Article
- HIV Prevalence and Characteristics Among Patients With AIDS-Defining and Non-AIDS-Defining Cancers in a Tertiary Hospital in Kenya.JCO global oncology · 2023Article
- A Case of Central Venous Catheter-Related Bacteremia Caused byCase reports in infectious diseases · 2023Article
- Cancer Patient Acceptance of HIV Screening at a Large Tertiary Cancer Center.JNCI cancer spectrum · 2022Article
- Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.The oncologist · 2022Article
- Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Prevalence and predictors of HIV screening in invasive cervical cancer: a 10 year cohort study.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2020Article
- Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I.The oncologist · 2016Article
- HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center.Journal of oncology practice · 2015Article
- HIV testing and burden of HIV infection in black cancer patients in Johannesburg, South Africa: a cross-sectional study.BMC cancer · 2015Article
- Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000.PloS one · 2015Article
- Integration of HIV and cervical cancer screening perceptions and preferences of communities in Uganda.BMC women's health · 2015Article
- Testing for human immunodeficiency virus among cancer survivors under age 65 in the United States.Preventing chronic disease · 2014Article
- Integration of HIV and cervical cancer screening perceptions of healthcare providers and policy makers in Uganda.BMC public health · 2014Article
- Lung cancer in HIV Infection.Clinical lung cancer · 2012Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
Human immunodeficiency virus (HIV)-infected individuals are at high risk of malignancies. However, it is not currently the standard of care to routinely test cancer patients for HIV. In 2006, the Centers for Disease Control and Prevention recommended HIV testing in all health care settings, calling for standard nontargeted "opt-out" HIV screening. For a variety of reasons, routine opt-out HIV testing is still not widely used in the United States. Although many barriers to routine opt-out HIV testing have been addressed, such opt-out HIV testing continues to be conducted primarily in venues that target specific patient populations such as pregnant women. Although opt-out testing has been piloted in emergency departments, less emphasis has been placed on opt-out HIV testing in other clinical settings. In this article, the background, rationale, and evidence for supporting opt-out HIV testing as routine care for cancer patients are presented. In addition, evidence is discussed for the potential of opt-out HIV testing to improve clinical outcomes by facilitating appropriate HIV management during cancer treatment for individuals who are found to be HIV positive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.